ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING
November 14, 2014 01:05 ET
|
Ablynx
GHENT, Belgium, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014...
ABLYNX ANNOUNCES ITS BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2014
November 13, 2014 01:09 ET
|
Ablynx
REGULATED INFORMATION
A period of good pipeline progress towards later stage clinical trials, a major alliance in the field of immuno-oncology and a strengthened financial position
GHENT,...
ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT RESULTS WITH ANTI-RSV NANOBODY, ALX-0171, AT 9th INTERNATIONAL RESPIRATORY SYNCYTIAL VIRUS SYMPOSIUM
November 06, 2014 01:06 ET
|
Ablynx
ALX-0171 has first-in-class potential for the treatment of RSV infections
On track to start first-in-infant Phase IIa study before the end of 2014
GHENT, Belgium, Nov. 6, 2014 (GLOBE NEWSWIRE)...
ABLYNX'S ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE DEMONSTRATES A BIOAVAILABILITY OF MORE THAN 80% AFTER SUBCUTANEOUS INJECTION
October 23, 2014 01:07 ET
|
Ablynx
GHENT, Belgium, Oct. 23, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced positive results from the Phase I bioavailability study of the subcutaneous formulation of its...
ABLYNX ANNOUNCES WARRANT EXERCISE
October 21, 2014 01:17 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree...
ABLYNX ESTABLISHES SPONSORED LEVEL I ADR PROGRAMME IN THE UNITED STATES
September 05, 2014 01:04 ET
|
Ablynx
GHENT, Belgium, Sept. 5, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced the launch of a Sponsored Level I American Depository Receipt (ADR) programme in the United States in...
ABLYNX SIGNS EXCLUSIVE LICENSE AGREEMENT WITH EDDINGPHARM TO DEVELOP AND COMMERCIALISE ITS ANTI-TNFa NANOBODY IN GREATER CHINA
September 01, 2014 01:05 ET
|
Ablynx
GHENT, Belgium, Sept. 1, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has expanded its relationship with Eddingpharm, one of the leading Chinese specialty...
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2014
August 28, 2014 01:08 ET
|
Ablynx
GHENT, Belgium, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced its results for the six-month period ending 30 June 2014, which have been prepared in accordance with...
ABLYNX WILL ANNOUNCE ITS HALF-YEAR RESULTS FOR 2014 WITH WEBCAST
August 21, 2014 01:05 ET
|
Ablynx
GHENT, Belgium, Aug. 21, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its half-year results for 2014 on Thursday 28 August 2014 at 7.00 am CET.
The Ablynx management team...
ABLYNX AWARDED EU2.1 MILLION GRANT TO SUPPORT DEVELOPMENT OF NOVEL NANOBODIES(R) FOR OCULAR APPLICATIONS
August 13, 2014 01:04 ET
|
Ablynx
GHENT, Belgium, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it has been awarded a €2.1 million grant by the Flemish Agency for Innovation by Science...